Shehab Mohamed: Recognizing Isolated Thrombocytopenia as a Presentation of MDS
Shehab Mohamed, Hematologist at hammed Medical Corporation, shared a post on Linkedin about recent article he and his colleauges co-authored, published in Expert Review of Anticancer Therapy, adding:
“Here we go !
Pleased to share our newly published review:
‘Myelodysplastic syndromes/neoplasms presenting with isolated thrombocytopenia: a poorly understood pathophysiology, difficult to diagnose, and challenging to treat entity’
Published in Expert Review of Anticancer Therapy.
In this review, we explore MDS presenting with isolated thrombocytopenia (MDS-IT)—an uncommon and often underrecognized phenotype that can closely mimic immune thrombocytopenia (ITP). We discuss its pathophysiology, diagnostic challenges, distinction from ITP and CCUS, the significance of isolated del(20q), and current therapeutic considerations.
I am grateful to all my co-authors for their valuable contributions and collaboration.
A special thank you to Amer Zeidan and Jan Philipp Bewersdorf from Yale School of Medicine for their supervision, mentorship, and invaluable guidance throughout this work and my colleague Mohammed Elmourtada Abdulgayoom Abdulrahman Al-Mashdali Rowan Mesilhy
To link to this article.
I hope this review contributes to greater recognition of this challenging MDS phenotype and helps stimulate further research in an area where important diagnostic and therapeutic uncertainties remain.”
Title: Myelodysplastic syndromes/neoplasms presenting with isolated thrombocytopenia: a poorly understood pathophysiology, difficult to diagnose, and challenging to treat entity
Authors: Shehab F. Mohamed, Mohammed Abdulgayoom, Abdulrahman F. Al-Mashdali, Rowan Mesilhy, Jan Philipp Bewersdorf, Amer M. Zeidan
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 30, 2026, 16:40Amrita Sarkar: Advancing the Diagnosis of Anti-PF4 Syndromes
-
Oct 30, 2026, 16:35James Garrard: Driving Innovation in Stroke Care Through Global Collaboration
-
Oct 30, 2026, 16:19Cesar de Almeida Neto: Hemo 2026 Roundtable Focuses on the Challenges of Patient Blood Management
-
Oct 30, 2026, 16:01Marilena Vrana: The Case for Retaining Immunoglobulins on the EU Critical Medicines List
-
Oct 30, 2026, 15:53Ilenia Calcaterra: Patient Blood Management Across Complex Hematological Conditions
-
Oct 30, 2026, 15:40Isabella Presch: The Practicalities of Gene Therapy Adoption in Hemophilia
-
Oct 30, 2026, 15:12Edward C.C. Wong: Navigating the Implications of the 2026 ASH Guidelines for Blood Donation
-
Oct 30, 2026, 14:53Pall T. Onundarson: Anticoagulation Guidelines Under the Influence of Pharmaceuticalisation
-
Oct 30, 2026, 14:27Isabella Presch: From Innovation to Accessibility in Cell and Gene Therapy